Ibrexafungerp:作用机制,临床和翻译科学
Adelynne H Walley1, Lauren N Dupuis1, Erica L Woodahl1,2
1Skaggs School of Pharmacy, University of Montana, Missoula, Montana, USA.
Clinical and translational science
|September 19, 2025
概括
一种新型抗真菌药物Ibrexafungerp通过向真菌细胞壁来有效治疗阴性真菌病 (VVC) 和复发性VVC. 它的独特机制为富可纳耐药病例提供了替代方案.
科学领域:
- 菌类学 菌类学是指菌类学.
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- Vulvovaginal candidiasis (VVC) 和复发性VVC (RVVC) 是常见的疾病,通常用醇抗真菌药物治疗.
- 流可纳耐药性是VVC管理中的一个新兴挑战.
- Ibrexafungerp代表了一种具有独特作用机制的新类抗真菌剂.
研究的目的:
- 审查ibrexafungerp对VVC和RVVC的监管批准,临床疗效和安全性.
- 分析ibrexafungerp的独特作用机制和药理动力学/药理动力学特性.
- 评估ibrexafungerp作为抗可纳抗性VVC的潜在治疗方法.
主要方法:
- 对监管文件和关键临床试验的审查 (DOVE,VANISH303).
- 对IBREXAFUNGERP的向β-1,3-葡萄糖合成酶的机制的分析.
- 在VVC和RVVC的背景下进行药理动力学和药理动力学评估.
主要成果:
- 在临床试验中,Ibrexafungerp的疗效与可纳相美,且优于安慰剂.
- 该药物向β-(1,3) - 葡萄糖合成酶,导致真菌细胞溶解.
- 伊布雷克萨格柏在阴道组织中表现出良好的分布和有效性,特别是在较低的pH值下.
结论:
- 伊布雷克萨芬格尔普已被批准用于VVC和RVVC,提供了一个新的治疗选择.
- 它独特的作用机制使其适合于对可纳耐药性感染.
- 目前正在进行的研究正在探索其在怀孕,哺乳期和侵入性真菌感染中的应用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
Transducer Mechanism: Nuclear Receptors
2.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.4K


